ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the second quarter 2024 after the U.S. market close on Tuesday, August 6th, 2024. Company management will host a conference call to disc ...

The average comprises four short-term price targets ranging from a low of $7 to a high of $11, with a standard deviation of $2.06. While the lowest estimate indicates an increase of 40% from the current price level, the most optimistic estimate points to a 120% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. Price, Consensus and EPS Surprise Accordi ...

The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive. There are several stocks that passed through the screen and MaxCyte, Inc. (MXCT) is one of them. Here are the key reasons why this stock is a solid choice for "trend" investing. However, it's not enough to look at the price change for ...

ROCKVILLE, Md., May 29, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced Company management will participate at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5th at 2:40 pm CT. A live and archived webcast of the event wi ...

ROCKVILLE, Md., May 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced it has entered into a strategic platform license (SPL) agreement with Legend Biotech, a global leader in cell therapy. Under the terms of the SPL, Legend Biotech obtains a n ...

ROCKVILLE, Md., May 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced it has entered into a strategic platform license (SPL) agreement with Legend Biotech, a global leader in cell therapy. About MaxCyte At MaxCyte, we pursue cell engineering e ...

MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript May 7, 2024 4:30 PM ET Company Participants Erik Abdow - Investor Relations Maher Masoud - President & Chief Executive Officer Douglas Swirsky - Chief Financial Officer Conference Call Participants Daniel Arias - Stifel Matt Larew - William Blair Jacob Johnson - Stephens Jacqueline Kisa - TD Cowen Operator Good day, and thank you for standing by. Welcome to the MaxCyte First Quarter 2024 Earnings Conference Call. At this time all participants are ...

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 35.71%. A quarter ago, it was expected that this company would post a loss of $0.10 per share when it actually produced a loss of $0.05, delivering a surprise of 50%.Over the last four quarters, the company has surpassed con ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission file number: 001-40674 MaxCyte, Inc. (Exact name of registrant as specified in its charter) Delaware 52-2210438 (State o ...

Exhibit 99.1 MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance ROCKVILLE, MD, May 7, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell- engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced its first quarter ended March 31, 2024 financial results and updated its 2024 guidance. First Quarter High ...